Advantage of delayed whole-body FDG-PET imaging for tumour detection.
about
Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time.Time sensitivity factor of single pulmonary nodule: a new cancer characteristic metabolic parameter by (18) F-FDG PET.18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and bDiagnostic value of EBUS-TBNA for lung cancer with non-enlarged lymph nodes: a study in a tuberculosis-endemic country.Positron emission tomography in cancer research and treatment.Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a proMetabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma.Radiofrequency ablation of lung tumors: imaging features of the postablation zoneEvaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric DiseaseCharacteristic CT Findings After Percutaneous Cryoablation Treatment of Malignant Lung Nodules.Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PETDual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.Usefulness of additional delayed regional F-18 Fluorodeoxy-Glucose Positron Emission Tomography in the lymph node staging of Non-Small Cell Lung Cancer patients.Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging.Dual-time-point 18F-FDG PET/CT in patients with colorectal cancer: clinical value of early delayed scanning.When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.Dual-time-point positron emission tomography findings of benign mediastinal fluorine-18-fluorodeoxyglucose uptake in tuberculosis-endemic region.18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.Feasibility of detecting small intestinal disease by FDG-PET/CT.Dual Time Point (18)F-FDG PET/CT Imaging Identifies Bilateral Renal Tuberculosis in an Immunocompromised Patient with an Unknown Primary MalignancyDynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation.Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application.Considering the Relationship between Quantitative Parameters and Prognostic Factors in Breast Cancer: Can Mean Standardized Uptake Value be an Alternative to Maximum Standardized Uptake Value?Unusual False-Positive Mesenteric Lymph Nodes Detected by PET/CT in a Metastatic Survey of Lung Cancer.A statistical clustering approach to visualizing the relationship between early and delayed images in whole-body FDG-PET.Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake.Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.Feasibility of assessing [(18)F]FDG lung metabolism with late dynamic PET imaging.The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.TOTAL-BODY PET: MAXIMIZING SENSITIVITY TO CREATE NEW OPPORTUNITIES FOR CLINICAL RESEARCH AND PATIENT CARE.A kinetic solution for the paradoxical difference between F-Dopa and methionine.(18)F-FDG uptake of the spinal cord was decreased after conventional dose radiotherapy in esophageal cancer patients.Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis.The usefulness of fully three-dimensional OSEM algorithm on lymph node metastases from lung cancer with 18F-FDG PET/CT.Diagnostic value of dual time-point 18 F-FDG PET/CT versus single time-point imaging for detection of mediastinal nodal metastasis in non-small cell lung cancer patients: a meta-analysis.Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosis-endemic region.Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.
P2860
Q33628752-DAE417E8-25A4-4541-8A2E-31A1E886A64AQ33736016-42093988-82AB-43E6-8520-246C13E23F7EQ33823389-969E896D-1A27-4AFE-868C-4BB8F8EA4285Q33833869-59EEA8B5-B248-4712-84CE-8E9A5C8698B4Q35081118-6A26C807-B167-4C40-9FC7-B46D29BABC6AQ35104354-2917BBA7-49DF-4F02-8B48-8D3D64819D64Q35535634-260D2E00-89A5-47F7-8212-D90D34B5021FQ36087385-FC9190F9-AA1A-4E73-9AC8-7AC37650A03CQ36194121-8DC03CD1-C4D3-47B3-8C13-EDCFDD267B4CQ36207050-2564E53F-E1C6-4F90-8E2F-7F36B508C2E5Q36337401-B58A4612-722E-4095-BB8D-CC0C38D04556Q36454757-4CA93CE4-5E4E-43EC-BC2E-0792E6A4F59EQ36618941-FAAD2667-EC29-4FE8-AB24-B606800FBE95Q37446915-3E631219-22C5-4149-B27B-0B944138B993Q37810810-90CF3E80-6EAF-4367-9F98-8066F3036ABFQ38001642-619E8CD3-FB37-492B-818A-E12DDA7DFF3BQ38077707-28F8F811-E8B8-4005-9F55-6C304CD488AAQ38482859-3616F976-D338-4615-A8FA-8EE4378675FBQ38568419-4796839A-8908-4D6D-B2A4-3B6D0248BDC8Q39000737-5F27868E-000B-4588-B38A-C71B28013E12Q40393387-6B1B736D-234D-4C95-AF6F-62F27BBF263BQ40839672-AC52852D-E1FF-4450-B075-0EC208D7A210Q41248866-A54E127E-EDEF-487A-B132-1BD1A7BCD70DQ41878745-4F58E687-A494-4C5C-A124-78C318C183EAQ41983073-83E41E18-E454-4AC0-AA91-DE2F58B99FE1Q42376460-439299A0-C14A-4C39-BFBF-DE17FC116737Q42426569-5117AF71-0EA0-476F-B018-210BD94A7463Q42915774-CE2A83A9-1BBB-4CDF-A263-CA1C366DEB98Q45148353-7BEBEA17-3BFC-42FF-96CB-9945D710D52EQ45840219-49927E74-6FB9-45F4-BC38-F8C6DA2E1774Q45937107-A1343E4D-617F-4A5E-A234-056BA4B13ED3Q45952058-CB282CE0-D307-46E7-A383-4A254179F28AQ46035229-D7888D44-699C-4A7C-B834-3834A7346AD3Q48248518-4121E917-B8B4-435E-9133-8456CA76EA4DQ50983784-B46BD062-B112-415D-86A3-ABEA7FAA549DQ51542474-C9366C03-795C-4F19-84EE-3FE74ED98C2BQ51613268-3C259CE1-FF2B-4BAE-91C5-8C5553781F7FQ53063299-B2FF1232-63FF-44F8-99CD-3D57ADC3D098Q53090206-CA41466E-D80B-4BD1-980A-223F30FE2E58Q53093553-FBBA5BB3-D5E8-47A8-8102-BEA41FC23AFE
P2860
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@en
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@nl
type
label
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@en
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@nl
prefLabel
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@en
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@nl
P2093
P356
P1476
Advantage of delayed whole-body FDG-PET imaging for tumour detection.
@en
P2093
Akaizawa T
Yamaguchi K
P2888
P304
P356
10.1007/S002590100537
P577
2001-06-01T00:00:00Z